Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ROCKET PHARMACEUTICALS, INC. (RCKT)

Rocket Pharmaceuticals closes up to $150 million Hercules loan, $35 million funded

Mixed Impact 4 of 5 financing Written later

Rocket Pharmaceuticals entered a Loan and Security Agreement with Hercules Capital on September 30, 2026, providing up to $150.0 million in senior secured term loans, with $35.0 million funded at closing. The company also issued warrants to the lenders for 1,755,853 shares of common stock at $2.99 per share, which adds potential dilution, and the loans are secured by substantially all of the company's assets.

Key points

  • Tranche 1-A advance of $35.0 million funded September 30, 2026; further tranches total up to $115.0 million at the company's option or the lenders' approval
  • Loans mature October 1, 2030, with interest at the greater of prime or 6.75%, plus 2.40%
  • Warrants for 1,755,853 shares at $2.99 per share; 409,699 shares exercisable after the Tranche 1-A funding
  • Prepayment charges of 3.00%, 2.00% or 1.00% depending on timing; minimum cash covenant not tested while market capitalization exceeds $600.0 million

The filing

CompanyROCKET PHARMACEUTICALS, INC. (RCKT)
Form8-K, current report
Filed with the SECOct 6, 2026, 5:15 PM ET
Accession number0001140361-26-038818

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation3.02 Unregistered Equity Sale7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.